Previous 10 | Next 10 |
SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2020 / Hagens Berman urges Allakos Inc. ( NASDAQ:ALLK ) investors who have suffered significant losses to submit their losses now . Only four days remain until the May 11, 2020 lead plaintiff deadline in a securities fraud class action that has been...
SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2020 / Hagens Berman urges Allakos Inc. ( NASDAQ:ALLK ) investors who have suffered significant losses to submit their losses now . Only five days remain until the May 11, 2020 lead plaintiff deadline in a securities fraud class action that has be...
New York, New York--(Newsfile Corp. - May 5, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Allakos Inc. (NASDAQ: ALLK) ("Allakos" or the "Company") of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities cla...
SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2020 / Hagens Berman urges Allakos Inc. ( NASDAQ:ALLK ) investors who have suffered significant losses to submit their losses now . The May 11, 2020 lead plaintiff deadline in a securities fraud class action that has been filed against the company...
SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases, including the upcoming May 11, 2020 lead plaintiff...
-- Antolimab treatment provided durable symptom improvement and blood and tissue eosinophil depletion -- -- Symptomatic benefit increased with duration of antolimab treatment -- REDWOOD CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasda...
SAN FRANCISCO, April 28, 2020 (GLOBE NEWSWIRE) -- Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases, including the upcoming May 11, 2020 lead plaintiff app...
SAN FRANCISCO, April 22, 2020 (GLOBE NEWSWIRE) -- Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases, including upcoming application deadlines, can be ...
REDWOOD CITY, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of four oral and three post...
Another biotech IPO has beaten the market blues. Keros Therapeutics (KROS) finished the week up 35%, affirming that the biotech industry won't be deterred by current market volatility. Oncology biotech Keros Therapeutics priced its upsized IPO at the high end to raise $96 million at a $325 m...
News, Short Squeeze, Breakout and More Instantly...
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety pro...
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chr...
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for...